Recent Updates on GLP-1 Therapies

Second-generation (also known as atypical) antipsychotics are increasingly used as adjunctive therapy for patients with major depressive disorder who have an inadequate or partial response to antidepressants. This course reviews the clinical rationale for their use, highlights newly approved options, and examines key safety, efficacy, and monitoring considerations. You will gain practical guidance to support patient selection, counseling, and shared decision-making when these agents are incorporated into depression management.HOSTRachel Maynard, PharmDGameChangers Podcast Host and Clinical Editor, CEimpactLead Editor, PyrlsGUESTSarah Grady, PharmD, BCPS, BCPPProfessor of Pharmacy Practice, Clinical PharmacistDrake University/Broadlawns Medical CenterGET CE FOR THIS LISTENING!The GameChangers Clinical Update Series for Pharmacists delivers 52 expert-led podcast episodes and 30+ hours of clinically actionable continuing education, all for a one-time purchase of just $99—that’s less than $3 per hour for high-impact learning you can apply immediately in practice. Click here to enroll. PRACTICE RESOURCEReceive the exclusive Practice Resource to use as a reference guide for this episode by purchasing the GameChangers Clinical Update Series. CPE REDEMPTIONThis course is accredited for continuing pharmacy education! Click the link below that applies to you to take the exam and evaluation to claim credit:If you are already enrolled in this course, click here to redeem your credit. To purchase the Clinical Update Series and claim your CPE credit, click here or to purchase this course individually, click here.  CPE INFORMATIONLearning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Explain the role of second-generation (atypical) antipsychotics as adjunctive therapy in the management of major depressive disorder.2. Identify pharmacist-relevant considerations for counseling, monitoring, and risk benefit assessment when second-generation antipsychotics are used for depression.Rachel Maynard and Sarah Grady have no relevant financial relationships to disclose.0.05 CEU/0.5 HrUAN: 0107-0000-26-059-H01-PInitial release date: 3/16/2026Expiration date: 3/16/2027Additional CPE details can be found here.Follow CEimpact on Social Media:LinkedInInstagram

GLP‑1 receptor agonists continue to generate clinical and media buzz, with new formulations, new approvals, and expanding areas of research. This course explores key updates, including the FDA approval of the first oral GLP‑1 for chronic weight management and ongoing investigations into GLP‑1 therapies for conditions beyond diabetes and obesity. You will gain a timely overview of recent developments in GLP‑1s and how pharmacists can anticipate and support their evolving role in patient care.HOSTRachel Maynard, PharmDGameChangers Podcast Host and Clinical Editor, CEimpactLead Editor, PyrlsGUESTChristine Schumacher, PharmD, BCPS, BCACP, BCCP, BC-ADM, CDCES, FCCPProfessor, Pharmacy Practice and Clinical PharmacistMidwestern UniversityGET CE FOR THIS LISTENING!The GameChangers Clinical Update Series for Pharmacists delivers 52 expert-led podcast episodes and 30+ hours of clinically actionable continuing education, all for a one-time purchase of just $99—that’s less than $3 per hour for high-impact learning you can apply immediately in practice. Click here to enroll.  PRACTICE RESOURCEReceive the exclusive Practice Resource to use as a reference guide for this episode by purchasing the GameChangers Clinical Update Series. CPE REDEMPTIONThis course is accredited for continuing pharmacy education! Click the link below that applies to you to take the exam and evaluation to claim credit:If you are already enrolled in this course, click here to redeem your credit. To purchase the Clinical Update Series and claim your CPE credit, click here or to purchase this course individually, click here. CPE INFORMATIONLearning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Summarize recent regulatory and clinical updates related to GLP‑1 receptor agonists, including new formulations.2. Describe emerging areas of research into the use of GLP‑1 therapies beyond diabetes and obesity treatment.Rachel Maynard has no relevant financial relationships with ineligible companies to disclose. Christie Schumacher is a speaker for and is on the advisory board for Abbott. All relevant financial relationships have been mitigated.0.1 CEU/1.0 HrUAN: 0107-0000-26-081-H01-PInitial release date: 3/9/2026Expiration date: 3/9/2027Additional CPE details can be found here.Follow CEimpact on Social Media:LinkedInInstagram

Recent changes to childhood vaccine recommendations have introduced shared clinical decision‑making for several immunizations that were previously universally recommended, creating confusion among patients and providers alike. This course explains what shared clinical decision‑making means in the context of immunizations, examines how it affects pediatric vaccine discussions, and highlights opportunities for pharmacists to support informed, individualized conversations with patients and caregivers. You will gain clarity on how to apply shared clinical decision‑making principles—alongside proven health coaching strategies—to strengthen patient trust and foster more meaningful dialogue in pharmacy practice.HOSTRachel Maynard, PharmDGameChangers Podcast Host and Clinical Editor, CEimpactLead Editor, PyrlsGUESTElizabeth Skoy, PharmD, RPhProfessorNorth Dakota State UniversityGET CE FOR THIS LISTENING!The GameChangers Clinical Update Series for Pharmacists delivers 52 expert-led podcast episodes and 30+ hours of clinically actionable continuing education, all for a one-time purchase of just $99—that’s less than $3 per hour for high-impact learning you can apply immediately in practice. Click here to enroll. PRACTICE RESOURCEReceive the exclusive Practice Resource to use as a reference guide for this episode by purchasing the GameChangers Clinical Update Series. CPE REDEMPTIONThis course is accredited for continuing pharmacy education! Click the link below that applies to you to take the exam and evaluation to claim credit:If you are already enrolled in this course, click here to redeem your credit. To purchase the Clinical Update Series and claim your CPE credit, click here or to purchase this course individually, click here.  CPE INFORMATIONLearning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Describe shared clinical decision-making and how it applies to recent pediatric vaccine recommendations.2. Identify the pharmacist's roles in counseling, education, and facilitating shared clinical decision-making conversations with patients and caregivers. Rachel Maynard and Elizabeth Skoy have no relevant financial relationships with ineligible companies to disclose. 0.05 CEU/0.5 HrUAN: 0107-0000-26-077-H01-PInitial release date: 3/2/2026Expiration date: 3/2/2027Additional CPE details can be found here.Follow CEimpact on Social Media:LinkedInInstagram

As gabapentin climbs the ranks to become one of the most prescribed medications in the U.S., questions about its safety and scope of use are also rising. This episode explores recent trends in gabapentin use, highlights key patient safety concerns, and examines pharmacist-led opportunities to reduce risks through education and medication review. You will walk away with timely insights to help navigate the growing complexities and responsibilities associated with gabapentin use.HOSTRachel Maynard, PharmDGameChangers Podcast Host and Clinical Editor, CEimpactLead Editor, PyrlsGUESTNakia Duncan, PharmD BCGP, BCPSAssociate Professor/ Pain& Palliative Care Clinical PharmacistTexas Tech Health Science Center - School of PharmacyGET CE FOR THIS LISTENING!The GameChangers Clinical Update Series for Pharmacists delivers 52 expert-led podcast episodes and 30+ hours of clinically actionable continuing education, all for a one-time purchase of just $99—that’s less than $3 per hour for high-impact learning you can apply immediately in practice. Click here to enroll. PRACTICE RESOURCEPurchase the Clinical Update Series or this course individually to receive the exclusive downloadable practice resource handout to use as a reference guide to the podcast. CPE REDEMPTIONThis course is accredited for continuing pharmacy education! Click the link below that applies to you to take the exam and evaluation:If you are already enrolled in this course, click here to redeem your credit. To purchase the Clinical Update Series and claim your CPE credit, click here or to purchase this course individually, click here.  CPE INFORMATIONLearning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Summarize recent national prescribing trends and safety concerns associated with gabapentin use.2. Identify pharmacist-led strategies to support safe use, patient education, and medication review involvinggabapentin.Rachel Maynard and Nakia Duncan have no relevant financial relationships with ineligible companies to disclose. 0.05 CEU/0.5 HrUAN: 0107-0000-26-053-H01-PInitial release date: 2/23/2026Expiration date: 2/23/2027Additional CPE details can be found here.Follow CEimpact on Social Media:LinkedInInstagram

Recent updates to U.S. guidelines for HIV post‑exposure prophylaxis (PEP) provide modernized recommendations for both non‑occupational and occupational exposures — reflecting advances in antiretroviral therapy and evolving evidence. This course summarizes key changes, including preferred regimens, testing/follow‑up modifications, and special‑population considerations, and explores how these updates influence clinical practice. You will gain the practical knowledge needed to inform prompt PEP decision‑making, patient counseling, and care coordination.HOSTRachel Maynard, PharmDGameChangers Podcast Host and Clinical Editor, CEimpactLead Editor, PyrlsGUESTKenric Ware, Pharm D Clinical Associate Professor of Pharmacy PracticeMercer UniversityGET CE FOR THIS LISTENING!The GameChangers Clinical Update Series for Pharmacists delivers 52 expert-led podcast episodes and 30+ hours of clinically actionable continuing education, all for a one-time purchase of just $99—that’s less than $3 per hour for high-impact learning you can apply immediately in practice. Click here to enroll. PRACTICE RESOURCEReceive the exclusive Practice Resource to use as a reference guide for this episode by purchasing the GameChangers Clinical Update Series. CPE REDEMPTIONThis course is accredited for continuing pharmacy education! Click the link below that applies to you to take the exam and evaluation to claim credit:If you are already enrolled in this course, click here to redeem your credit. To purchase the Clinical Update Series and claim your CPE credit, click here or to purchase this course individually, click here.  CPE INFORMATIONLearning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Identify current guideline recommendations for initiating HIV PEP after occupational and non-occupational exposure.2. Describe key considerations for selecting and managing HIV PEP regimens.Rachel Maynard and Kenric Ware have no relevant financial relationships with ineligible companies to disclose. 0.05 CEU/0.5 HrUAN: 0107-0000-26-052-H01-PInitial release date: 2/16/2026Expiration date: 2/16/2027Additional CPE details can be found here.Follow CEimpact on Social Media:LinkedInInstagram

Recent developments in HIV prevention — including the FDA approval of a 6‑month injectable option and updated clinical guidance — are changing the landscape of Pre-Exposure Prophylaxis (PrEP) therapy. This course reviews the latest developments, compares prevention strategies, and examines how these changes affect PrEP delivery, counseling, and monitoring. You will gain timely insights to better counsel patients, support adherence, and contribute to prevention strategies in your practice.HOSTRachel Maynard, PharmDGameChangers Podcast Host and Clinical Editor, CEimpactLead Editor, PyrlsGUESTDavid Hachey, PharmD, AAHIVP Professor Idaho State University GET CE FOR THIS LISTENING!The GameChangers Clinical Update Series for Pharmacists delivers 52 expert-led podcast episodes and 30+ hours of clinically actionable continuing education, all for a one-time purchase of just $99—that’s less than $3 per hour for high-impact learning you can apply immediately in practice. Click here to enroll. PRACTICE RESOURCEReceive the exclusive Practice Resource to use as a reference guide for this episode by purchasing the GameChangers Clinical Update Series. CPE REDEMPTIONThis course is accredited for continuing pharmacy education! Click the link below that applies to you to take the exam and evaluation:If you are already enrolled in this course, click here to redeem your credit. To purchase the Clinical Update Series and claim your CPE credit, click here or to purchase this course individually, click here.  CPE INFORMATIONLearning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Describe key new HIV PrEP therapy options recently approved or recommended, including their dosing schedules and clinical indications.2. Identify pharmacist responsibilities when counseling patients about PrEP, including initiation, adherence, monitoring, and risk-benefit discussions. Rachel Maynard and David Hachey have no relevant financial relationships to disclose.0.05 CEU/0.5 HrUAN: 0107-0000-26-049-H01-PInitial release date: 2/9/2026Expiration date: 2/9/2027Additional CPE details can be found here.Follow CEimpact on Social Media:LinkedInInstagram

With the number of biosimilar products steadily increasing, pharmacists play a central role in ensuring their appropriate use in inflammatory conditions. This episode highlights approval pathways, interchangeability, and real-world challenges pharmacists may face when integrating biosimilars into care plans. You will walk away better prepared to support prescribers, counsel patients, and contribute to cost-effective, evidence-informed therapy decisions.HOSTRachel Maynard, PharmDGameChangers Podcast Host and Clinical Editor, CEimpactLead Editor, PyrlsGUESTReemal Zaheer, PharmD, CSPPharmacistJohns Hopkins MedicineGAMECHANGERS CLINICAL UPDATE SERIESThe Clinical Update Series for Pharmacists delivers 52 expert-led podcast episodes and 30+ hours of clinically actionable continuing education, all for a one-time purchase of just $99—that’s less than $3 per hour for high-impact learning you can apply immediately in practice. Click here to enroll. PRACTICE RESOURCEPurchase the Clinical Update Series or this course individually to receive the exclusive downloadable practice resource handout to use as a reference guide to the podcast. CPE REDEMPTIONThis course is accredited for continuing pharmacy education! Click the link below that applies to you to take the exam and evaluation:If you are already enrolled in this course, click here to redeem your credit. To purchase the Clinical Update Series and claim your CPE credit, click here or to purchase this course individually, click here.  CPE INFORMATIONLearning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Explain the role of biosimilars in the treatment of inflammatory conditions.2. Describe considerations for the pharmacist when evaluating or counseling on biosimilar therapies.Rachel Maynard and Reemal Zaheer have no relevant financial relationships with ineligible companies to disclose. 0.075 CEU/0.75 HrUAN: 0107-0000-26-045-H01-PInitial release date: 2/2/2026Expiration date: 2/2/2027Additional CPE details can be found here.Follow CEimpact on Social Media:LinkedInInstagram

Menopausal hormone therapy has long carried a boxed warning (formerly a "black box warning") that may not accurately reflect the therapy's risk-benefit profile for all patients. This course discusses the FDA's recent removal of boxed warnings for select hormone therapy (HT) products, the rationale for this change, and how evolving guidance may impact patient care. You will explore strategies to support evidence-based counseling and individualized decision-making for patients considering HT.HOSTRachel Maynard, PharmDGameChangers Podcast Host and Clinical Editor, CEimpactLead Editor, PyrlsGUESTErin Raney, PharmDProfessorMidwestern University College of PharmacyGAMECHANGERS CLINICAL UPDATE SERIESThe Clinical Update Series for Pharmacists delivers 52 expert-led podcast episodes and 30+ hours of clinically actionable continuing education, all for a one-time purchase of just $99—that’s less than $3 per hour for high-impact learning you can apply immediately in practice. Click here to enroll. PRACTICE RESOURCEPurchase the Clinical Update Series or this course individually to receive the exclusive downloadable practice resource handout to use as a reference guide to the podcast. CPE REDEMPTIONThis course is accredited for continuing pharmacy education! Click the link below that applies to you to take the exam and evaluation:If you are already enrolled in this course, click here to redeem your credit. To purchase the Clinical Update Series and claim your CPE credit, click here or to purchase this course individually, click here.  CPE INFORMATIONLearning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Summarize the FDA's updated position on boxed warnings for menopausal hormone therapy.2. Identify key considerations for pharmacists when counseling patients about the benefits and risks of hormone therapy.Rachel Maynard and Erin Raney have no relevant financial relationships with ineligible companies to disclose. 0.075 CEU/0.75 HrUAN: 0107-0000-26-044-H01-PInitial release date: 1/26/2026Expiration date: 1/26/2027Additional CPE details can be found here.Follow CEimpact on Social Media:LinkedInInstagramFollow CEimpact on Social Media:LinkedInInstagram

Ranitidine — once withdrawn from the market over safety concerns — was recently re‑approved by the FDA in a reformulated version, raising important questions for pharmacists and patients alike. This course outlines the FDA’s recent approval, reviews the reformulated product's changes (including manufacturing and labeling), and examines practical considerations for dispensing, counseling, and patient safety. You will gain clarity on when ranitidine may be appropriate for use (again) and how to guide patients confidently in its safe use.HOSTRachel Maynard, PharmDGameChangers Podcast Host and Clinical Editor, CEimpactLead Editor, PyrlsGUESTK. Ashley Garling-Nanez, PharmDAssistant Director of ProgramUT Center of Health CommunicationsGAMECHANGERS CLINICAL UPDATE SERIESThe Clinical Update Series for Pharmacists delivers 52 expert-led podcast episodes and 30+ hours of clinically actionable continuing education, all for a one-time purchase of just $99—that’s less than $3 per hour for high-impact learning you can apply immediately in practice. Click here to enroll. PRACTICE RESOURCEPurchase the Clinical Update Series or this course individually to receive the exclusive downloadable practice resource handout to use as a reference guide to the podcast. CPE REDEMPTIONThis course is accredited for continuing pharmacy education! Click the link below that applies to you to take the exam and evaluation:If you are already enrolled in this course, click here to redeem your credit. To purchase the Clinical Update Series and claim your CPE credit, click here. CPE INFORMATIONLearning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Summarize the major safety and regulatory issues that prompted ranitidine's withdrawal, and the changes made in the reformulated product approved in 2025.2. Describe pharmacist‑relevant considerations for dispensing, patient counseling, and transition from alternative acid‑reducing therapies.Rachel Maynard and K. Ashley Garling-Nanez have no relevant financial relationships with ineligible companies to disclose. 0.05 CEU/0.5 HrUAN: 0107-0000-26-043-H01-PInitial release date: 1/19/2026Expiration date: 1/19/2027Additional CPE details can be found here.Follow CEimpact on Social Media:LinkedInInstagram

Recent years have seen a troubling resurgence of whooping cough and measles — diseases many thought were largely controlled — highlighting the continuing importance of vaccination, surveillance, and community education. This course reviews the latest evidence on global and local trends, explores the factors driving renewed outbreaks, and discusses the key roles of pharmacists in prevention and early detection. You will gain insights to be better prepared to support immunization efforts, patient counseling, and public health awareness in response to this resurgence.HOSTRachel Maynard, PharmDGameChangers Podcast Host and Clinical Editor, CEimpactLead Editor, PyrlsGUESTChristina O'Connor, PharmD, BCPS, BCIDPClinical Pharmacy ManagerMayo ClinicGAMECHANGERS CLINICAL UPDATE SERIESThe Clinical Update Series for Pharmacists delivers 52 expert-led podcast episodes and 30+ hours of clinically actionable continuing education, all for a one-time purchase of just $99—that’s less than $3 per hour for high-impact learning you can apply immediately in practice. Click here to enroll. PRACTICE RESOURCEPurchase the Clinical Update Series or this course individually to receive the exclusive downloadable practice resource handout to use as a reference guide to the podcast. CPE REDEMPTIONThis course is accredited for continuing pharmacy education! Click the link below that applies to you to take the exam and evaluation:If you are already enrolled in this course, click here to redeem your credit. To purchase the Clinical Update Series and claim your CPE credit, click here. CPE INFORMATIONLearning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Describe recent epidemiologic trends in pertussis and measles resurgence and factors contributing to increased incidence.2. Identify the pharmacist's responsibilities for promoting vaccination, encouraging timely immunization, supporting outbreak prevention, and providing patient education.Rachel Maynard and Christina O'Connor have no relevant financial relationships to disclose.0.075 CEU/0.75 HrUAN: 0107-0000-26-038-H01-PInitial release date: 1/12/2026Expiration date: 1/12/2027Additional CPE details can be found here.Follow CEimpact on Social Media:LinkedInInstagram